{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T05:28:22Z","timestamp":1794547702849,"version":"4.9.1"},"reference-count":133,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Immunol"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1038\/s41577-026-01318-x","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T08:01:01Z","timestamp":1782806461000},"page":"851-865","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["T cell engagers in autoimmune diseases"],"prefix":"10.1038","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2873-5135","authenticated-orcid":false,"given":"Ricardo","family":"Grieshaber-Bouyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1607-5587","authenticated-orcid":false,"given":"Lei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8740-9615","authenticated-orcid":false,"given":"Georg","family":"Schett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick A.","family":"Baeuerle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"key":"1318_CR1","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/d41573-025-00085-z","volume":"24","author":"M Bhandari","year":"2025","unstructured":"Bhandari, M., Smith, J. F., Capra, E. & Yang, G. The race to reset autoimmune diseases. Nat. Rev. Drug Discov. 24, 498\u2013499 (2025).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1318_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/antib9030034","author":"D Zahavi","year":"2020","unstructured":"Zahavi, D. & Weiner, L. Monoclonal antibodies in cancer therapy. Antibodies https:\/\/doi.org\/10.3390\/antib9030034 (2020).","journal-title":"Antibodies"},{"key":"1318_CR3","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1126\/science.147.3660.873","volume":"147","author":"E Moeller","year":"1965","unstructured":"Moeller, E. Contact-induced cytotoxicity by lymphoid cells containing foreign isoantigens. Science 147, 873\u2013879 (1965).","journal-title":"Science"},{"key":"1318_CR4","doi-asserted-by":"publisher","first-page":"2531223","DOI":"10.1080\/19420862.2025.2531223","volume":"17","author":"C Bergamaschi","year":"2025","unstructured":"Bergamaschi, C. et al. Innovative strategies for T cell engagers for cancer immunotherapy. mAbs 17, 2531223 (2025).","journal-title":"mAbs"},{"key":"1318_CR5","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell, K. M. & Kochenderfer, J. N. Long-term outcomes following CAR T cell therapy: what we know so far. Nat. Rev. Clin. Oncol. 20, 359\u2013371 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1318_CR6","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1073\/pnas.83.5.1453","volume":"83","author":"UD Staerz","year":"1986","unstructured":"Staerz, U. D. & Bevan, M. J. Hybrid hybridoma producing a bispecific monoclonal antibody that can focus effector T-cell activity. Proc. Natl Acad. Sci. USA 83, 1453\u20131457 (1986).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1318_CR7","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.pharmthera.2012.07.013","volume":"136","author":"D Nagorsen","year":"2012","unstructured":"Nagorsen, D., Kufer, P., Baeuerle, P. A. & Bargou, R. Blinatumomab: a historical perspective. Pharmacol. Ther. 136, 334\u2013342 (2012).","journal-title":"Pharmacol. Ther."},{"key":"1318_CR8","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1007\/s40265-025-02187-9","volume":"85","author":"YY Syed","year":"2025","unstructured":"Syed, Y. Y. Catumaxomab: first approval. Drugs 85, 957\u2013963 (2025).","journal-title":"Drugs"},{"key":"1318_CR9","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.molimm.2005.03.007","volume":"43","author":"S Offner","year":"2006","unstructured":"Offner, S., Hofmeister, R., Romaniuk, A., Kufer, P. & Baeuerle, P. A. Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells. Mol. Immunol. 43, 763\u2013771 (2006).","journal-title":"Mol. Immunol."},{"key":"1318_CR10","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/ijc.20908","volume":"115","author":"P Hoffmann","year":"2005","unstructured":"Hoffmann, P. et al. Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-\/CD3-bispecific single-chain antibody construct. Int. J. Cancer 115, 98\u2013104 (2005).","journal-title":"Int. J. Cancer"},{"key":"1318_CR11","doi-asserted-by":"publisher","first-page":"e0183390","DOI":"10.1371\/journal.pone.0183390","volume":"12","author":"SL Ross","year":"2017","unstructured":"Ross, S. L. et al. Bispecific T cell engager (BiTE\u00ae) antibody constructs can mediate bystander tumor cell killing. PLoS ONE 12, e0183390 (2017).","journal-title":"PLoS ONE"},{"key":"1318_CR12","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1038\/s41591-024-02964-1","volume":"30","author":"L Bucci","year":"2024","unstructured":"Bucci, L. et al. Bispecific T cell engager therapy for refractory rheumatoid arthritis. Nat. Med. 30, 1593\u20131601 (2024).","journal-title":"Nat. Med."},{"key":"1318_CR13","doi-asserted-by":"publisher","first-page":"114071","DOI":"10.1016\/j.ejca.2024.114071","volume":"204","author":"M Subklewe","year":"2024","unstructured":"Subklewe, M. et al. Application of blinatumomab, a bispecific anti-CD3\/CD19 T-cell engager, in treating severe systemic sclerosis: a case study. Eur. J. Cancer 204, 114071 (2024).","journal-title":"Eur. J. Cancer"},{"key":"1318_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2025.06.042","author":"T Ruck","year":"2025","unstructured":"Ruck, T. et al. CD19xCD3 T cell engager blinatumomab effective in refractory generalized myasthenic syndromes. Mol. Ther. https:\/\/doi.org\/10.1016\/j.ymthe.2025.06.042 (2025).","journal-title":"Mol. Ther."},{"key":"1318_CR15","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1038\/s41591-026-04238-4","volume":"32","author":"C Duesing","year":"2026","unstructured":"Duesing, C. et al. Bispecific T cell engagers for the treatment of severe, treatment-refractory autoimmune-mediated connective tissue diseases. Nat. Med. 32, 1530\u20131542 (2026).","journal-title":"Nat. Med."},{"key":"1318_CR16","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1056\/NEJMc2516228","volume":"394","author":"A Gottschlich","year":"2026","unstructured":"Gottschlich, A. et al. Blinatumomab in combined immune thrombocytopenia and antiphospholipid syndrome. N. Engl. J. Med. 394, 1030\u20131033 (2026).","journal-title":"N. Engl. J. Med."},{"key":"1318_CR17","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1056\/NEJMc2408786","volume":"391","author":"M Hagen","year":"2024","unstructured":"Hagen, M. et al. BCMA-targeted T-cell-engager therapy for autoimmune disease. N. Engl. J. Med. 391, 867\u2013869 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1318_CR18","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1056\/NEJMc2407150","volume":"391","author":"T Alexander","year":"2024","unstructured":"Alexander, T., Kronke, J., Cheng, Q., Keller, U. & Kronke, G. Teclistamab-induced remission in refractory systemic lupus erythematosus. N. Engl. J. Med. 391, 864\u2013866 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1318_CR19","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/s41581-023-00720-1","volume":"19","author":"DS Pisetsky","year":"2023","unstructured":"Pisetsky, D. S. Pathogenesis of autoimmune disease. Nat. Rev. Nephrol. 19, 509\u2013524 (2023).","journal-title":"Nat. Rev. Nephrol."},{"key":"1318_CR20","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.autrev.2005.03.003","volume":"4","author":"P de Buys","year":"2005","unstructured":"de Buys, P., Khanna, D. & Furst, D. E. Hemopoietic stem cell transplantation in rheumatic diseases\u2014an update. Autoimmun. Rev. 4, 442\u2013449 (2005).","journal-title":"Autoimmun. Rev."},{"key":"1318_CR21","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1016\/S0140-6736(23)01126-1","volume":"402","author":"G Schett","year":"2023","unstructured":"Schett, G., Mackensen, A. & Mougiakakos, D. CAR T-cell therapy in autoimmune diseases. Lancet 402, 2034\u20132044 (2023).","journal-title":"Lancet"},{"key":"1318_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-025-01349-4","author":"J Avouac","year":"2026","unstructured":"Avouac, J. et al. Roads and detours for CAR T cell therapy in autoimmune diseases. Nat. Rev. Drug Discov. https:\/\/doi.org\/10.1038\/s41573-025-01349-4 (2026).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1318_CR23","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/nrneurol.2017.81","volume":"13","author":"PA Muraro","year":"2017","unstructured":"Muraro, P. A. et al. Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis. Nat. Rev. Neurol. 13, 391\u2013405 (2017).","journal-title":"Nat. Rev. Neurol."},{"key":"1318_CR24","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jaut.2018.06.002","volume":"92","author":"T Alexander","year":"2018","unstructured":"Alexander, T. et al. Hematopoietic stem cell therapy for autoimmune diseases - clinical experience and mechanisms. J. Autoimmun. 92, 35\u201346 (2018).","journal-title":"J. Autoimmun."},{"key":"1318_CR25","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41584-024-01139-z","volume":"20","author":"G Schett","year":"2024","unstructured":"Schett, G. et al. Advancements and challenges in CAR T cell therapy in autoimmune diseases. Nat. Rev. Rheumatol. 20, 531\u2013544 (2024).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1318_CR26","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/s41584-023-01036-x","volume":"19","author":"M Feldmann","year":"2023","unstructured":"Feldmann, M., Maini, R. N., Soriano, E. R., Strand, V. & Takeuchi, T. 25 years of biologic DMARDs in rheumatology. Nat. Rev. Rheumatol. 19, 761\u2013766 (2023).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1318_CR27","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20251652","author":"PA Baeuerle","year":"2026","unstructured":"Baeuerle, P. A., Sauer, K., Grieshaber-Bouyer, R. & Michaelson, J. S. T cell engagers emerge as a compelling therapeutic modality. J. Exp. Med. https:\/\/doi.org\/10.1084\/jem.20251652 (2026).","journal-title":"J. Exp. Med."},{"key":"1318_CR28","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/s41573-020-00092-2","volume":"20","author":"DSW Lee","year":"2021","unstructured":"Lee, D. S. W., Rojas, O. L. & Gommerman, J. L. B cell depletion therapies in autoimmune disease: advances and mechanistic insights. Nat. Rev. Drug Discov. 20, 179\u2013199 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1318_CR29","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1586\/14737140.5.1.39","volume":"5","author":"F Ravandi","year":"2005","unstructured":"Ravandi, F. & O\u2019Brien, S. Alemtuzumab. Expert Rev. Anticancer Ther. 5, 39\u201351 (2005).","journal-title":"Expert Rev. Anticancer Ther."},{"key":"1318_CR30","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3389\/fonc.2018.00163","volume":"8","author":"TM Pierpont","year":"2018","unstructured":"Pierpont, T. M., Limper, C. B. & Richards, K. L. Past, present, and future of rituximab-the world\u2019s first oncology monoclonal antibody therapy. Front. Oncol. 8, 163 (2018).","journal-title":"Front. Oncol."},{"key":"1318_CR31","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1056\/NEJMoa032534","volume":"350","author":"JC Edwards","year":"2004","unstructured":"Edwards, J. C. et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med. 350, 2572\u20132581 (2004).","journal-title":"N. Engl. J. Med."},{"key":"1318_CR32","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa0909905","volume":"363","author":"JH Stone","year":"2010","unstructured":"Stone, J. H. et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N. Engl. J. Med. 363, 221\u2013232 (2010).","journal-title":"N. Engl. J. Med."},{"key":"1318_CR33","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa2028564","volume":"384","author":"VP Werth","year":"2021","unstructured":"Werth, V. P. et al. Rituximab versus mycophenolate mofetil in patients with pemphigus vulgaris. N. Engl. J. Med. 384, 2295\u20132305 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1318_CR34","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/art.27233","volume":"62","author":"JT Merrill","year":"2010","unstructured":"Merrill, J. T. et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheumatol. 62, 222\u2013233 (2010).","journal-title":"Arthritis Rheumatol."},{"key":"1318_CR35","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1002\/art.34359","volume":"64","author":"BH Rovin","year":"2012","unstructured":"Rovin, B. H. et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study. Arthritis Rheumatol. 64, 1215\u20131226 (2012).","journal-title":"Arthritis Rheumatol."},{"key":"1318_CR36","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1056\/NEJMoa1917246","volume":"383","author":"SL Hauser","year":"2020","unstructured":"Hauser, S. L. et al. Ofatumumab versus teriflunomide in multiple sclerosis. N. Engl. J. Med. 383, 546\u2013557 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1318_CR37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2516150","author":"RA Furie","year":"2026","unstructured":"Furie, R. A. et al. Efficacy and safety of obinutuzumab in active systemic lupus erythematosus. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa2516150 (2026).","journal-title":"N. Engl. J. Med."},{"key":"1318_CR38","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMc2107725","volume":"385","author":"D Mougiakakos","year":"2021","unstructured":"Mougiakakos, D. et al. CD19-targeted CAR T cells in refractory systemic lupus erythematosus. N. Engl. J. Med. 385, 567\u2013569 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1318_CR39","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","volume":"390","author":"F Muller","year":"2024","unstructured":"Muller, F. et al. CD19 CAR T-cell therapy in autoimmune disease - a case series with follow-up. N. Engl. J. Med. 390, 687\u2013700 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1318_CR40","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","volume":"28","author":"A Mackensen","year":"2022","unstructured":"Mackensen, A. et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat. Med. 28, 2124\u20132132 (2022).","journal-title":"Nat. Med."},{"key":"1318_CR41","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1056\/NEJMc2506740","volume":"393","author":"L Bucci","year":"2025","unstructured":"Bucci, L. et al. BCMA T-cell engager therapy in patients with refractory autoimmune disease. N. Engl. J. Med. 393, 1544\u20131547 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1318_CR42","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S0140-6736(25)02515-2","volume":"407","author":"J Duque-Afonso","year":"2026","unstructured":"Duque-Afonso, J., Rummelt, C., Forster, K., Zeiser, R. & Mougiakakos, D. BCMA-CD3 T-cell engager as salvage therapy for multirefractory primary immune thrombocytopenia. Lancet 407, 489\u2013491 (2026).","journal-title":"Lancet"},{"key":"1318_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2025.10.026","author":"AN Stutz","year":"2025","unstructured":"Stutz, A. N. et al. Mosunetuzumab, a CD20xCD3 bispecific T-cell engager, in granulomatosis with polyangiitis. Ann. Rheum. Dis. https:\/\/doi.org\/10.1016\/j.ard.2025.10.026 (2025).","journal-title":"Ann. Rheum. Dis."},{"key":"1318_CR44","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1182\/blood-2015-03-633685","volume":"126","author":"MJ Borowitz","year":"2015","unstructured":"Borowitz, M. J. et al. Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children\u2019s Oncology Group study AALL0232. Blood 126, 964\u2013971 (2015).","journal-title":"Blood"},{"key":"1318_CR45","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","volume":"131","author":"N Gokbuget","year":"2018","unstructured":"Gokbuget, N. et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood 131, 1522\u20131531 (2018).","journal-title":"Blood"},{"key":"1318_CR46","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa2312948","volume":"391","author":"MR Litzow","year":"2024","unstructured":"Litzow, M. R. et al. Blinatumomab for MRD-negative acute lymphoblastic leukemia in adults. N. Engl. J. Med. 391, 320\u2013333 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1318_CR47","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/cei.12481","volume":"180","author":"AP Trouvin","year":"2015","unstructured":"Trouvin, A. P. et al. Usefulness of monitoring of B cell depletion in rituximab-treated rheumatoid arthritis patients in order to predict clinical relapse: a prospective observational study. Clin. Exp. Immunol. 180, 11\u201318 (2015).","journal-title":"Clin. Exp. Immunol."},{"key":"1318_CR48","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1002\/art.22400","volume":"56","author":"K Vos","year":"2007","unstructured":"Vos, K. et al. Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis. Arthritis Rheumatol. 56, 772\u2013778 (2007).","journal-title":"Arthritis Rheumatol."},{"key":"1318_CR49","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1002\/art.30152","volume":"63","author":"EM Vital","year":"2011","unstructured":"Vital, E. M. et al. Reduced-dose rituximab in rheumatoid arthritis: efficacy depends on degree of B cell depletion. Arthritis Rheumatol. 63, 603\u2013608 (2011).","journal-title":"Arthritis Rheumatol."},{"key":"1318_CR50","doi-asserted-by":"publisher","first-page":"R131","DOI":"10.1186\/ar2798","volume":"11","author":"M Nakou","year":"2009","unstructured":"Nakou, M. et al. Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response. Arthritis Res. Ther. 11, R131 (2009).","journal-title":"Arthritis Res. Ther."},{"key":"1318_CR51","doi-asserted-by":"publisher","first-page":"3909","DOI":"10.1002\/art.22967","volume":"56","author":"YK Teng","year":"2007","unstructured":"Teng, Y. K. et al. Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment. Arthritis Rheumatol. 56, 3909\u20133918 (2007).","journal-title":"Arthritis Rheumatol."},{"key":"1318_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2025.06.2120","author":"C Tur","year":"2025","unstructured":"Tur, C. et al. Effects of different B-cell-depleting strategies on the lymphatic tissue. Ann. Rheum. Dis. https:\/\/doi.org\/10.1016\/j.ard.2025.06.2120 (2025).","journal-title":"Ann. Rheum. Dis."},{"key":"1318_CR53","first-page":"abstr. 2641","volume":"77","author":"R Grieshaber-Bouyer","year":"2025","unstructured":"Grieshaber-Bouyer R. et al. Cizutamig, a BCMA T-cell engager: preclinical to clinical translation of design optimization for the treatment of autoimmune diseases. Arthritis Rheumatol. 77, abstr. 2641 (2025).","journal-title":"Arthritis Rheumatol."},{"key":"1318_CR54","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.ard.2025.01.043","volume":"84","author":"E Siegert","year":"2025","unstructured":"Siegert, E. et al. Teclistamab in relapsed systemic sclerosis after autologous haematopoietic stem cell transplantation. Ann. Rheum. Dis. 84, 653\u2013656 (2025).","journal-title":"Ann. Rheum. Dis."},{"key":"1318_CR55","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.ard.2025.09.012","volume":"85","author":"E Phithak","year":"2026","unstructured":"Phithak, E. et al. Teclistamab-induced rapid remission in refractory Anti-Jo-1 antisynthetase syndrome. Ann. Rheum. Dis. 85, 212\u2013215 (2026).","journal-title":"Ann. Rheum. Dis."},{"key":"1318_CR56","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/S0092-8674(02)01194-7","volume":"111","author":"ME Call","year":"2002","unstructured":"Call, M. E., Pyrdol, J., Wiedmann, M. & Wucherpfennig, K. W. The organizing principle in the formation of the T cell receptor-CD3 complex. Cell 111, 967\u2013979 (2002).","journal-title":"Cell"},{"key":"1318_CR57","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.coi.2009.03.009","volume":"21","author":"MS Krangel","year":"2009","unstructured":"Krangel, M. S. Mechanics of T cell receptor gene rearrangement. Curr. Opin. Immunol. 21, 133\u2013139 (2009).","journal-title":"Curr. Opin. Immunol."},{"key":"1318_CR58","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/s41392-021-00823-w","volume":"6","author":"K Shah","year":"2021","unstructured":"Shah, K., Al-Haidari, A., Sun, J. & Kazi, J. U. T cell receptor (TCR) signaling in health and disease. Signal Transduct. Target. Ther. 6, 412 (2021).","journal-title":"Signal Transduct. Target. Ther."},{"key":"1318_CR59","first-page":"E5891","volume":"114","author":"L Li","year":"2017","unstructured":"Li, L. et al. Ionic CD3-Lck interaction regulates the initiation of T-cell receptor signaling. Proc. Natl Acad. Sci. USA 114, E5891\u2013E5899 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1318_CR60","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1038\/s41590-020-0732-3","volume":"21","author":"FA Hartl","year":"2020","unstructured":"Hartl, F. A. et al. Noncanonical binding of Lck to CD3\u03b5 promotes TCR signaling and CAR function. Nat. Immunol. 21, 902\u2013913 (2020).","journal-title":"Nat. Immunol."},{"key":"1318_CR61","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.imbio.2008.11.014","volume":"214","author":"C Haas","year":"2009","unstructured":"Haas, C. et al. Mode of cytotoxic action of T cell-engaging BiTE antibody MT110. Immunobiology 214, 441\u2013453 (2009).","journal-title":"Immunobiology"},{"key":"1318_CR62","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/356607a0","volume":"356","author":"FA Harding","year":"1992","unstructured":"Harding, F. A., McArthur, J. G., Gross, J. A., Raulet, D. H. & Allison, J. P. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 356, 607\u2013609 (1992).","journal-title":"Nature"},{"key":"1318_CR63","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1126\/science.1158545","volume":"321","author":"R Bargou","year":"2008","unstructured":"Bargou, R. et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 321, 974\u2013977 (2008).","journal-title":"Science"},{"key":"1318_CR64","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1182\/blood-2015-06-649111","volume":"126","author":"G Zugmaier","year":"2015","unstructured":"Zugmaier, G. et al. Long-term survival and T-cell kinetics in relapsed\/refractory ALL patients who achieved MRD response after blinatumomab treatment. Blood 126, 2578\u20132584 (2015).","journal-title":"Blood"},{"key":"1318_CR65","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s43018-019-0004-z","volume":"1","author":"L Wu","year":"2020","unstructured":"Wu, L. et al. Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation. Nat. Cancer 1, 86\u201398 (2020).","journal-title":"Nat. Cancer"},{"key":"1318_CR66","doi-asserted-by":"publisher","first-page":"101161","DOI":"10.1016\/j.xcrm.2023.101161","volume":"4","author":"M Boulch","year":"2023","unstructured":"Boulch, M. et al. A major role for CD4+ T cells in driving cytokine release syndrome during CAR T cell therapy. Cell Rep. Med. 4, 101161 (2023).","journal-title":"Cell Rep. Med."},{"key":"1318_CR67","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s42003-021-02995-1","volume":"5","author":"MA Al-Aghbar","year":"2022","unstructured":"Al-Aghbar, M. A., Jainarayanan, A. K., Dustin, M. L. & Roffler, S. R. The interplay between membrane topology and mechanical forces in regulating T cell receptor activity. Commun. Biol. 5, 40 (2022).","journal-title":"Commun. Biol."},{"key":"1318_CR68","doi-asserted-by":"publisher","first-page":"2234","DOI":"10.1016\/j.bpj.2024.05.020","volume":"123","author":"J Rogers","year":"2024","unstructured":"Rogers, J., Bajur, A. T., Salaita, K. & Spillane, K. M. Mechanical control of antigen detection and discrimination by T and B cell receptors. Biophys. J. 123, 2234\u20132255 (2024).","journal-title":"Biophys. J."},{"key":"1318_CR69","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03127-w","volume":"9","author":"Y Razvag","year":"2018","unstructured":"Razvag, Y., Neve-Oz, Y., Sajman, J., Reches, M. & Sherman, E. Nanoscale kinetic segregation of TCR and CD45 in engaged microvilli facilitates early T cell activation. Nat. Commun. 9, 732 (2018).","journal-title":"Nat. Commun."},{"key":"1318_CR70","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/s41590-018-0131-1","volume":"19","author":"WL Lo","year":"2018","unstructured":"Lo, W. L. et al. Lck promotes Zap70-dependent LAT phosphorylation by bridging Zap70 to LAT. Nat. Immunol. 19, 733\u2013741 (2018).","journal-title":"Nat. Immunol."},{"key":"1318_CR71","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1146\/annurev-immunol-042617-053335","volume":"36","author":"BB Au-Yeung","year":"2018","unstructured":"Au-Yeung, B. B., Shah, N. H., Shen, L. & Weiss, A. ZAP-70 in signaling, biology, and disease. Annu. Rev. Immunol. 36, 127\u2013156 (2018).","journal-title":"Annu. Rev. Immunol."},{"key":"1318_CR72","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.immuni.2013.08.036","volume":"39","author":"J Huang","year":"2013","unstructured":"Huang, J. et al. A single peptide-major histocompatibility complex ligand triggers digital cytokine secretion in CD4+\u00a0T cells. Immunity 39, 846\u2013857 (2013).","journal-title":"Immunity"},{"key":"1318_CR73","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007398","author":"K Meetze","year":"2023","unstructured":"Meetze, K., Mehta, N. K., Li, B., Michaelson, J. S. & Baeuerle, P. A. CLN-978, a novel half-life extended CD19\/CD3\/HSA-specific T cell-engaging antibody construct with potent activity against B-cell malignancies with low CD19 expression. J. Immunother. Cancer https:\/\/doi.org\/10.1136\/jitc-2023-007398 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"1318_CR74","doi-asserted-by":"publisher","first-page":"e693","DOI":"10.1016\/S2352-3026(24)00186-8","volume":"11","author":"N van de Donk","year":"2024","unstructured":"van de Donk, N., Chari, A. & Mateos, M. V. Mechanisms of resistance against T-cell engaging bispecific antibodies in multiple myeloma: implications for novel treatment strategies. Lancet Haematol. 11, e693\u2013e707 (2024).","journal-title":"Lancet Haematol."},{"key":"1318_CR75","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1182\/blood.2022015956","volume":"140","author":"N Philipp","year":"2022","unstructured":"Philipp, N. et al. T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals. Blood 140, 1104\u20131118 (2022).","journal-title":"Blood"},{"key":"1318_CR76","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.ccell.2023.02.008","volume":"41","author":"MJ Friedrich","year":"2023","unstructured":"Friedrich, M. J. et al. The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients. Cancer Cell 41, 711\u2013725.e716 (2023).","journal-title":"Cancer Cell"},{"key":"1318_CR77","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1182\/blood.2023022823","volume":"144","author":"D Cortes-Selva","year":"2024","unstructured":"Cortes-Selva, D. et al. Correlation of immune fitness with response to teclistamab in relapsed\/refractory multiple myeloma in the MajesTEC-1 study. Blood 144, 615\u2013628 (2024).","journal-title":"Blood"},{"key":"1318_CR78","doi-asserted-by":"publisher","first-page":"e0141669","DOI":"10.1371\/journal.pone.0141669","volume":"10","author":"W Deisting","year":"2015","unstructured":"Deisting, W., Raum, T., Kufer, P., Baeuerle, P. A. & Munz, M. Impact of diverse immune evasion mechanisms of cancer cells on T cells engaged by EpCAM\/CD3-bispecific antibody construct AMG 110. PLoS ONE 10, e0141669 (2015).","journal-title":"PLoS ONE"},{"key":"1318_CR79","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1097\/CJI.0b013e318156750c","volume":"30","author":"K Brischwein","year":"2007","unstructured":"Brischwein, K. et al. Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class. J. Immunother. 30, 798\u2013807 (2007).","journal-title":"J. Immunother."},{"key":"1318_CR80","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1158\/1535-7163.MCT-24-0846","volume":"24","author":"D Wu","year":"2025","unstructured":"Wu, D. et al. Optimization of a novel 2 + 2 BCMA x CD3 bispecific antibody for minimized cytokine release and potent efficacy. Mol. Cancer Ther. 24, 1600\u20131610 (2025).","journal-title":"Mol. Cancer Ther."},{"key":"1318_CR81","doi-asserted-by":"publisher","first-page":"2584374","DOI":"10.1080\/19420862.2025.2584374","volume":"17","author":"O Abdelmotaleb","year":"2025","unstructured":"Abdelmotaleb, O. et al. Optimizing efficacy and safety of T cell bispecific antibodies: the interdependence of CD3 and tumor antigen binder affinities in FOLR1 and CEACAM5 2 + 1 TCBs. mAbs 17, 2584374 (2025).","journal-title":"mAbs"},{"key":"1318_CR82","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1158\/2159-8290.CD-23-0984","volume":"14","author":"O Nolan-Stevaux","year":"2024","unstructured":"Nolan-Stevaux, O. et al. AMG 509 (xaluritamig), an anti-STEAP1 XmAb 2+1 T-cell redirecting immune therapy with avidity-dependent activity against prostate cancer. Cancer Discov. 14, 90\u2013103 (2024).","journal-title":"Cancer Discov."},{"key":"1318_CR83","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.copbio.2009.10.013","volume":"20","author":"PY Muller","year":"2009","unstructured":"Muller, P. Y., Milton, M., Lloyd, P., Sims, J. & Brennan, F. R. The minimum anticipated biological effect level (MABEL) for selection of first human dose in clinical trials with monoclonal antibodies. Curr. Opin. Biotechnol. 20, 722\u2013729 (2009).","journal-title":"Curr. Opin. Biotechnol."},{"key":"1318_CR84","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2023.2181016","author":"K Ball","year":"2023","unstructured":"Ball, K., Dovedi, S. J., Vajjah, P. & Phipps, A. Strategies for clinical dose optimization of T cell-engaging therapies in oncology. mAbs https:\/\/doi.org\/10.1080\/19420862.2023.2181016 (2023).","journal-title":"mAbs"},{"key":"1318_CR85","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1002\/cpt.1396","volume":"106","author":"J Duell","year":"2019","unstructured":"Duell, J. et al. Bispecific antibodies in the treatment of hematologic malignancies. Clin. Pharmacol. Ther. 106, 781\u2013791 (2019).","journal-title":"Clin. Pharmacol. Ther."},{"key":"1318_CR86","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/psp4.12369","volume":"8","author":"J Schropp","year":"2019","unstructured":"Schropp, J., Khot, A., Shah, D. K. & Koch, G. Target-mediated drug disposition model for bispecific antibodies: properties, approximation, and optimal dosing strategy. CPT Pharmacomet. Syst. Pharmacol. 8, 177\u2013187 (2019).","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"1318_CR87","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-025-01134-8","author":"M Elmeliegy","year":"2025","unstructured":"Elmeliegy, M. et al. Dose optimization of elranatamab to mitigate the risk of cytokine release syndrome in patients with multiple myeloma. Target. Oncol. https:\/\/doi.org\/10.1007\/s11523-025-01134-8 (2025).","journal-title":"Target. Oncol."},{"key":"1318_CR88","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1172\/JCI40141","volume":"120","author":"HD Brightbill","year":"2010","unstructured":"Brightbill, H. D. et al. Antibodies specific for a segment of human membrane IgE deplete IgE-producing B cells in humanized mice. J. Clin. Invest. 120, 2218\u20132229 (2010).","journal-title":"J. Clin. Invest."},{"key":"1318_CR89","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/j.kint.2024.01.021","volume":"105","author":"L Seifert","year":"2024","unstructured":"Seifert, L. et al. An antigen-specific chimeric autoantibody receptor (CAAR) NK cell strategy for the elimination of anti-PLA2R1 and anti-THSD7A antibody-secreting cells. Kidney Int. 105, 886\u2013889 (2024).","journal-title":"Kidney Int."},{"key":"1318_CR90","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.molimm.2004.04.002","volume":"41","author":"M Zocher","year":"2004","unstructured":"Zocher, M. & Baeuerle, P. A. A bispecific single-chain antibody fusion protein for targeted depletion of autoreactive B cells via unstimulated human T lymphocytes. Mol. Immunol. 41, 511\u2013518 (2004).","journal-title":"Mol. Immunol."},{"key":"1318_CR91","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1335998","author":"L Perico","year":"2024","unstructured":"Perico, L. et al. Bi-specific autoantigen-T cell engagers as targeted immunotherapy for autoreactive B cell depletion in autoimmune diseases. Front. Immunol. https:\/\/doi.org\/10.3389\/fimmu.2024.1335998 (2024).","journal-title":"Front. Immunol."},{"key":"1318_CR92","doi-asserted-by":"publisher","first-page":"6317","DOI":"10.1172\/JCI138416","volume":"130","author":"J Lee","year":"2020","unstructured":"Lee, J. et al. Antigen-specific B cell depletion for precision therapy of mucosal pemphigus vulgaris. J. Clin. Invest. 130, 6317\u20136324 (2020).","journal-title":"J. Clin. Invest."},{"key":"1318_CR93","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1038\/s41587-022-01637-z","volume":"41","author":"S Oh","year":"2023","unstructured":"Oh, S. et al. Precision targeting of autoantigen-specific B cells in muscle-specific tyrosine kinase myasthenia gravis with chimeric autoantibody receptor T cells. Nat. Biotechnol. 41, 1229\u20131238 (2023).","journal-title":"Nat. Biotechnol."},{"key":"1318_CR94","doi-asserted-by":"publisher","unstructured":"Liu, J. et al. Precision targeting of autoreactive B cells in systemic lupus erythematosus using anti-9G4 idiotope synthetic immune receptor T cells. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2025.10.19.682634 (2026).","DOI":"10.1101\/2025.10.19.682634"},{"key":"1318_CR95","first-page":"abstr. 0837","volume":"76","author":"Y Xia","year":"2024","unstructured":"Xia Y. et al. Bispecific autoantigen-T cell engagers (BaiTE) to selectively target autoreactive B cells in antiphospholipid syndrome. Arthritis Rheumatol. 76, abstr. 0837 (2024).","journal-title":"Arthritis Rheumatol."},{"key":"1318_CR96","doi-asserted-by":"publisher","first-page":"2602993","DOI":"10.1080\/19420862.2025.2602993","volume":"18","author":"M Surowka","year":"2026","unstructured":"Surowka, M. et al. P329G-engager: a universal mix & match antibody-based adaptor platform for cancer immunotherapy. mAbs 18, 2602993 (2026).","journal-title":"mAbs"},{"key":"1318_CR97","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2117402119","author":"AJ Martinko","year":"2022","unstructured":"Martinko, A. J. et al. Switchable assembly and function of antibody complexes in vivo using a small molecule. Proc. Natl Acad. Sci. USA https:\/\/doi.org\/10.1073\/pnas.2117402119 (2022).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1318_CR98","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1136\/annrheumdis-2024-eular.3799","volume":"83","author":"R Domingo-Gonzalez","year":"2024","unstructured":"Domingo-Gonzalez, R. et al. POS1062 therapeutic potential of imvotamab, a CD20-targeted bispecific IgM T cell engager, for the treatment of refractory autoimmune disease patients. Ann. Rheum. Dis. 83, 935\u2013935 (2024).","journal-title":"Ann. Rheum. Dis."},{"key":"1318_CR99","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1002\/art.42784","volume":"76","author":"J Taubmann","year":"2024","unstructured":"Taubmann, J. et al. CD19 chimeric antigen receptor T cell treatment: unraveling the role of b cells in systemic lupus erythematosus. Arthritis Rheumatol. 76, 497\u2013504 (2024).","journal-title":"Arthritis Rheumatol."},{"key":"1318_CR100","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/s41375-024-02154-5","volume":"38","author":"C Riedhammer","year":"2024","unstructured":"Riedhammer, C. et al. Real-world analysis of teclistamab in 123 RRMM patients from Germany. Leukemia 38, 365\u2013371 (2024).","journal-title":"Leukemia"},{"key":"1318_CR101","doi-asserted-by":"publisher","first-page":"114075","DOI":"10.1016\/j.ejca.2024.114075","volume":"205","author":"A Geraud","year":"2024","unstructured":"Geraud, A. et al. Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive review. Eur. J. Cancer 205, 114075 (2024).","journal-title":"Eur. J. Cancer"},{"key":"1318_CR102","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","volume":"112","author":"A Freites-Martinez","year":"2021","unstructured":"Freites-Martinez, A., Santana, N., Arias-Santiago, S. & Viera, A. Using the common terminology criteria for adverse events (CTCAE - version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermosifiliogr. 112, 90\u201392 (2021).","journal-title":"Actas Dermosifiliogr."},{"key":"1318_CR103","doi-asserted-by":"publisher","DOI":"10.3390\/cells14161242","author":"P Anyfanti","year":"2025","unstructured":"Anyfanti, P. et al. Chimeric antigen receptor T cell immunotherapy for autoimmune rheumatic disorders: where are we now? Cells https:\/\/doi.org\/10.3390\/cells14161242 (2025).","journal-title":"Cells"},{"key":"1318_CR104","doi-asserted-by":"publisher","first-page":"e424","DOI":"10.1016\/S2665-9913(25)00091-8","volume":"7","author":"M Hagen","year":"2025","unstructured":"Hagen, M. et al. Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with autoimmune disease: an observational study. Lancet Rheumatol. 7, e424\u2013e433 (2025).","journal-title":"Lancet Rheumatol."},{"key":"1318_CR105","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1182\/blood.2023021860","volume":"142","author":"J Gust","year":"2023","unstructured":"Gust, J. BCMA-CAR T-cell treatment-associated parkinsonism. Blood 142, 1181\u20131183 (2023).","journal-title":"Blood"},{"key":"1318_CR106","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-5754","author":"G Nogueira Bezerra","year":"2025","unstructured":"Nogueira Bezerra, G. et al. Prophylactic intravenous immunoglobulin in patients receiving BCMA-targeted bispecific antibody therapy for multiple myeloma: a systematic review and meta-analysis. Blood https:\/\/doi.org\/10.1182\/blood-2025-5754 (2025).","journal-title":"Blood"},{"key":"1318_CR107","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1002\/cpt.3361","volume":"116","author":"M Elmeliegy","year":"2024","unstructured":"Elmeliegy, M. et al. Dosing strategies and quantitative clinical pharmacology for bispecific T-cell engagers development in oncology. Clin. Pharmacol. Ther. 116, 637\u2013646 (2024).","journal-title":"Clin. Pharmacol. Ther."},{"key":"1318_CR108","first-page":"705","volume":"16","author":"S Si","year":"2020","unstructured":"Si, S. & Teachey, D. T. Spotlight on tocilizumab in the treatment of CAR-T-cell-induced cytokine release syndrome: clinical evidence to date. Ther. Clin. Risk Manag. 16, 705\u2013714 (2020).","journal-title":"Ther. Clin. Risk Manag."},{"key":"1318_CR109","doi-asserted-by":"publisher","first-page":"eabo4271","DOI":"10.1126\/sciadv.abo4271","volume":"8","author":"PM Chen","year":"2022","unstructured":"Chen, P. M. et al. CD38 reduces mitochondrial fitness and cytotoxic T cell response against viral infection in lupus patients by suppressing mitophagy. Sci. Adv. 8, eabo4271 (2022).","journal-title":"Sci. Adv."},{"key":"1318_CR110","doi-asserted-by":"publisher","first-page":"e170580","DOI":"10.1001\/jamaoncol.2017.0580","volume":"3","author":"DA Berry","year":"2017","unstructured":"Berry, D. A. et al. Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis. JAMA Oncol. 3, e170580 (2017).","journal-title":"JAMA Oncol."},{"key":"1318_CR111","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-025-01141-w","author":"T Junt","year":"2025","unstructured":"Junt, T. et al. Defining immune reset: achieving sustained remission in autoimmune diseases. Nat. Rev. Immunol. https:\/\/doi.org\/10.1038\/s41577-025-01141-w (2025).","journal-title":"Nat. Rev. Immunol."},{"issue":"abstr. Suppl. 1","key":"1318_CR112","first-page":"s173","volume":"85","author":"L Bucci","year":"2026","unstructured":"Bucci, L. et al. \u201cImmune dimming\u201d with low-dose blinatumomab reverses the treatment-resistant state in rheumatoid arthritis. Ann. Rheum. Dis. 85, abstr. Suppl. 1, s173 (2026).","journal-title":"Ann. Rheum. Dis."},{"key":"1318_CR113","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-026-03069-5","author":"M Senior","year":"2026","unstructured":"Senior, M. & Grieshaber-Bouyer, R. B cell depletion in autoimmune disease: in vivo CAR-T or T cell engagers? Nat. Biotechnol. https:\/\/doi.org\/10.1038\/s41587-026-03069-5 (2026).","journal-title":"Nat. Biotechnol."},{"key":"1318_CR114","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.179433","author":"A Wilhelm","year":"2024","unstructured":"Wilhelm, A. et al. Selective CAR T cell-mediated B cell depletion suppresses IFN signature in SLE. JCI Insight https:\/\/doi.org\/10.1172\/jci.insight.179433 (2024).","journal-title":"JCI Insight"},{"key":"1318_CR115","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1056\/NEJMc2502297","volume":"392","author":"L Zhang","year":"2025","unstructured":"Zhang, L. et al. BCMA-targeted T-cell engager for autoimmune hemolytic anemia after CD19 CAR T-cell therapy. N. Engl. J. Med. 392, 2282\u20132284 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1318_CR116","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2026.01.020","author":"J Leon","year":"2026","unstructured":"Leon, J. et al. B-cell maturation antigen-targeted T-cell engager therapy combined with B-cell depletion for treatment of refractory HLA sensitization. Kidney Int. https:\/\/doi.org\/10.1016\/j.kint.2026.01.020 (2026).","journal-title":"Kidney Int."},{"key":"1318_CR117","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.1038\/s41591-023-02613-z","volume":"29","author":"OV Britanova","year":"2023","unstructured":"Britanova, O. V. et al. Targeted depletion of TRBV9+ T cells as immunotherapy in a patient with ankylosing spondylitis. Nat. Med. 29, 2731\u20132736 (2023).","journal-title":"Nat. Med."},{"key":"1318_CR118","first-page":"abstr. 1707","volume":"76","author":"S Glavaris","year":"2024","unstructured":"Glavaris S. et al. TRBV9-targeted bispecific T cell-engaging antibodies to reset the autoreactive T cell compartment in spondyloarthritis and HLA-DQ8 celiac disease. Arthritis Rheumatol. 76, abstr. 1707 (2024).","journal-title":"Arthritis Rheumatol."},{"key":"1318_CR119","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2024.106938","author":"J Weldon","year":"2024","unstructured":"Weldon, J., Regan, M., Bonett, M. & Scott, D. Abstract 1626 cytotoxic T lymphocyte-mediated killing of factor VIII-specific B lymphocytes using a bispecific immunoconjugate. J. Biol. Chem. https:\/\/doi.org\/10.1016\/j.jbc.2024.106938 (2024).","journal-title":"J. Biol. Chem."},{"key":"1318_CR120","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41573-024-00896-6","volume":"23","author":"C Klein","year":"2024","unstructured":"Klein, C., Brinkmann, U., Reichert, J. M. & Kontermann, R. E. The present and future of bispecific antibodies for cancer therapy. Nat. Rev. Drug Discov. 23, 301\u2013319 (2024).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1318_CR121","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1158\/2326-6066.CIR-19-0121","volume":"7","author":"L Wang","year":"2019","unstructured":"Wang, L., Hoseini, S. S., Xu, H., Ponomarev, V. & Cheung, N. K. Silencing Fc domains in T cell-engaging bispecific antibodies improves T-cell trafficking and antitumor potency. Cancer Immunol. Res. 7, 2013\u20132024 (2019).","journal-title":"Cancer Immunol. Res."},{"key":"1318_CR122","doi-asserted-by":"publisher","first-page":"12650","DOI":"10.1074\/jbc.M700820200","volume":"282","author":"D Muller","year":"2007","unstructured":"Muller, D. et al. Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin. J. Biol. Chem. 282, 12650\u201312660 (2007).","journal-title":"J. Biol. Chem."},{"key":"1318_CR123","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1002\/cmdc.201600374","volume":"11","author":"SB van Witteloostuijn","year":"2016","unstructured":"van Witteloostuijn, S. B., Pedersen, S. L. & Jensen, K. J. Half-life extension of biopharmaceuticals using chemical methods: alternatives to PEGylation. ChemMedChem 11, 2474\u20132495 (2016).","journal-title":"ChemMedChem"},{"key":"1318_CR124","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008733","author":"RP O\u2019Connell","year":"2024","unstructured":"O\u2019Connell, R. P. et al. Format-tuning of in vivo-launched bispecific T cell engager enhances efficacy against renal cell carcinoma. J. Immunother. Cancer https:\/\/doi.org\/10.1136\/jitc-2023-008733 (2024).","journal-title":"J. Immunother. Cancer"},{"key":"1318_CR125","doi-asserted-by":"publisher","first-page":"817","DOI":"10.4049\/jimmunol.174.2.817","volume":"174","author":"Q Gong","year":"2005","unstructured":"Gong, Q. et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J. Immunol. 174, 817\u2013826 (2005).","journal-title":"J. Immunol."},{"key":"1318_CR126","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2025.08.004","author":"H Lee","year":"2025","unstructured":"Lee, H., Lee, Y. & Chung, J. Characterization of anti-CD3 antibodies in clinically available bispecific T cell engagers. Semin. Hematol. https:\/\/doi.org\/10.1053\/j.seminhematol.2025.08.004 (2025).","journal-title":"Semin. Hematol."},{"key":"1318_CR127","doi-asserted-by":"publisher","first-page":"3921","DOI":"10.1158\/1078-0432.CCR-18-2752","volume":"25","author":"CL Zuch de Zafra","year":"2019","unstructured":"Zuch de Zafra, C. L. et al. Targeting multiple myeloma with AMG 424, a novel anti-CD38\/CD3 bispecific T-cell-recruiting antibody optimized for cytotoxicity and cytokine release. Clin. Cancer Res. 25, 3921\u20133933 (2019).","journal-title":"Clin. Cancer Res."},{"key":"1318_CR128","doi-asserted-by":"publisher","first-page":"1890411","DOI":"10.1080\/19420862.2021.1890411","volume":"13","author":"HK Malik-Chaudhry","year":"2021","unstructured":"Malik-Chaudhry, H. K. et al. TNB-486 induces potent tumor cell cytotoxicity coupled with low cytokine release in preclinical models of B-NHL. mAbs 13, 1890411 (2021).","journal-title":"mAbs"},{"key":"1318_CR129","doi-asserted-by":"publisher","first-page":"5514","DOI":"10.1182\/blood-2025-5514","volume":"146","author":"TM Kim","year":"2025","unstructured":"Kim, T. M. et al. Surovatamig (AZD0486), a CD19xCD3 T-cell engager (TCE), demonstrates high rate of minimal residual disease (MRD)\u2013negative complete responses in relapsed\/refractory (R\/R) diffuse large B-cell lymphoma (DLBCL), including in patients who previously progressed on CD20 TCE and CD19 CAR T-cell therapies. Blood 146, 5514\u20135514 (2025).","journal-title":"Blood"},{"key":"1318_CR130","first-page":"abstr. 0001","volume":"77","author":"G Bian","year":"2025","unstructured":"Bian G. et al. ATG-201, a novel steric hindrance-based masking CD19xCD3 T-cell engager (TCE) for the treatment of B cell-related autoimmune diseases. Arthritis Rheumatol. 77, abstr. 0001 (2025).","journal-title":"Arthritis Rheumatol."},{"key":"1318_CR131","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1182\/blood-2024-198745","volume":"144","author":"R Lawrence","year":"2024","unstructured":"Lawrence, R. et al. Pre-clinical evaluation of AZD5492, a novel CD8-guided T cell engager, for B-non Hodgkin lymphoma indications. Blood 144, 959\u2013959 (2024).","journal-title":"Blood"},{"key":"1318_CR132","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1158\/2326-6066.CIR-23-0189","volume":"11","author":"LA King","year":"2023","unstructured":"King, L. A. et al. A bispecific \u03b3\u03b4 T-cell engager targeting EGFR activates a potent V\u03b39V\u03b42 T cell-mediated immune response against EGFR-expressing tumors. Cancer Immunol. Res. 11, 1237\u20131252 (2023).","journal-title":"Cancer Immunol. Res."},{"key":"1318_CR133","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-93842-0","volume":"11","author":"L Haber","year":"2021","unstructured":"Haber, L. et al. Generation of T-cell-redirecting bispecific antibodies with differentiated profiles of cytokine release and biodistribution by CD3 affinity tuning. Sci. Rep. 11, 14397 (2021).","journal-title":"Sci. Rep."}],"container-title":["Nature Reviews Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41577-026-01318-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41577-026-01318-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41577-026-01318-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T13:01:32Z","timestamp":1793106092000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41577-026-01318-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":133,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1318"],"URL":"https:\/\/doi.org\/10.1038\/s41577-026-01318-x","relation":{},"ISSN":["1474-1733","1474-1741"],"issn-type":[{"value":"1474-1733","type":"print"},{"value":"1474-1741","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]},"assertion":[{"value":"19 May 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.G.-B. reports research support or honoraria from AbbVie, Alfasigma, Amgen, AstraZeneca, Bristol Myers Squibb, Candid Therapeutics, Cullinan Therapeutics, Epana Bio, Gilead, Kite, Johnson & Johnson, Kyverna Therapeutics, Lilly, Novartis, Pfizer, Roche, Sanofi, Xencor and UCB. L.W. is an employee of and holds stock in WuXi Biologics. G.S. reports speaker honoraria from Novartis, Johnson & Johnson, BMS and UCB. P.A.B. reports consulting honoraria and equity in Cullinan Therapeutics.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}